1035271-10-3

Basic information

• Product Name: methyl 4-(4-acetylpiperazin-1-yl)benzoate
• Synonyms: methyl 4-(4-acetylpiperazin-1-yl)benzoate
• CAS NO: 1035271-10-3
• Molecular Formula: C₁₄H₁₈N₂O₃
• Molecular Weight: 262.31
• Mol File: 1035271-10-3.mol

Chemical Properties

• Boiling Point: 460.2±40.0 °C(Predicted)
• Appearance: /
• Density: 1.182±0.06 g/cm3(Predicted)
• PKA: 2.31±0.10(Predicted)
• CAS DataBase Reference: methyl 4-(4-acetylpiperazin-1-yl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-(4-acetylpiperazin-1-yl)benzoate(1035271-10-3)
• EPA Substance Registry System: methyl 4-(4-acetylpiperazin-1-yl)benzoate(1035271-10-3)

Safety Data

• Hazardous Substances Data: 1035271-10-3(Hazardous Substances Data)

Upstream product

• 13889-98-0 N-acetylpiperidine 
• 403-33-8 methyl 4-flurobenzoate 
• 619-42-1 4-methoxycarbonylphenyl bromide 

Relevant articles and documents

Discovery of a Potent FLT3 Inhibitor (LT-850-166) with the Capacity of Overcoming a Variety of FLT3 Mutations

Secondary mutations of FLT3 have become the main mechanism of FLT3 inhibitor resistance that presents a significant clinical challenge. Herein, a series of pyrazole-3-amine derivatives were synthesized and optimized to overcome the common secondary resistance mutations of FLT3. The structure-activity relationship and molecular dynamics simulation studies illustrated that the ribose region of FLT3 could be occupied to help address the obstacle of secondary mutations. Among those derivatives, compound 67 exhibited potent and selective inhibitory activities against FLT3-ITD-positive acute myeloid leukemia (AML) cells and possessed equivalent potency against transformed BaF3 cells with a variety of secondary mutations. Besides, cellular mechanism assays demonstrated that 67 strongly inhibited phosphorylation of FLT3 and its downstream signaling factors, as well as induced cell cycle arrest and apoptosis in MV4-11 cells. In the MV4-11 xenograft models, 67 exhibited potent antitumor potency without obvious toxicity. Taken together, these results demonstrated that 67 might be a drug candidate for the treatment of FLT3-ITD-positive AML.

Optimization of 1H-indazol-3-amine derivatives as potent fibroblast growth factor receptor inhibitors

Fibroblast growth factor receptor (FGFR) is a potential target for cancer therapy because of its critical role in promoting cancer formation and progression. In a continuing effort to improve the cellular activity of hit compound 7r bearing an indazole scaffold, which was previously discovered by our group, several compounds harnessing fluorine substituents were designed, synthesized and biological evaluated. Besides, the region extended out to the ATP binding pocket toward solvent was also explored. Among them, compound 2a containing 2,6-difluoro-3-methoxyphenyl residue exhibited the most potent activities (FGFR1: less than 4.1?nM, FGFR2: 2.0?±?0.8?nM). More importantly, compound 2a showed an improved antiproliferative effect against KG1 cell lines and SNU16 cell lines with IC50 values of 25.3?±?4.6?nM and 77.4?±?6.2?nM respectively.

NOVEL COMPOUNDS

There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.